Clinical Trials | March 07, 2026
Roche’s Gazyva shows breakthrough results in Lupus phase III trial
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
Merck emphasized the broader significance of the findings
The facility is expected to become operational by FY2028-29
Emcure to distribute Roche's kidney transplant and anemia drugs in India
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
The new patents cover critical advancements in cochlear implant technology
Subscribe To Our Newsletter & Stay Updated
